| Scott C Felter I, DO | |
|
101 Erford Rd, Suite 101, Camp Hill, PA 17011-1802 | |
| (717) 975-8900 | |
| (717) 975-9400 |
| Full Name | Scott C Felter I |
|---|---|
| Gender | Male |
| Speciality | Hematology/oncology |
| Experience | 23 Years |
| Location | 101 Erford Rd, Camp Hill, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1821134404 | NPI | - | NPPES |
| 1018209800002 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | OS012266 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Pinnacle Health Hospitals | Harrisburg, PA | Hospital |
| Carlisle Regional Medical Center | Carlisle, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Upmc Hillman Cancer Center-pinnacle | 4284044934 | 37 |
News Archive
Celgene International Sàrl announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality. REVLIMID was also approved in June 2010 in combination with dexamethasone, for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy.
Isis Pharmaceuticals, Inc. announced today that it has initiated a Phase 1 study for ISIS-GSK3Rx and earned a $3 million milestone payment from GlaxoSmithKline.
At the first sign of a stroke, time is of the essence. For every minute of delay in treatment, people typically lose almost two million brain cells. Yet a new study presented at the Canadian Stroke Congress reveals that those delays - in getting the right tests and the right drugs - can be longer when people experience a stroke in a hospital.
A group of leading entrepreneurs and innovators will be gathering at the Royal Society of Medicine on Saturday 16 April to take part in the Society's 12th Medical Innovations Summit. Providing a twice-yearly platform for the presentation and discussion of inspirational ideas and developments in the field of medicine and healthcare, the Summits encourage innovators at the very beginning of their careers, as well as established clinicians and academics.
Takeda Pharmaceutical Company Limited today announced top-line results from the international, randomized, placebo-controlled, double-blind GEMINI II pivotal phase 3 trial. The trial evaluated vedolizumab in 1,115 patients with moderately to severely active Crohn's disease who have failed at least one conventional therapy, including TNFα antagonists.
› Verified 6 days ago
| Entity Name | Pinnacle Health Medical Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932143427 PECOS PAC ID: 7618960493 Enrollment ID: O20040407000180 |
News Archive
Celgene International Sàrl announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality. REVLIMID was also approved in June 2010 in combination with dexamethasone, for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy.
Isis Pharmaceuticals, Inc. announced today that it has initiated a Phase 1 study for ISIS-GSK3Rx and earned a $3 million milestone payment from GlaxoSmithKline.
At the first sign of a stroke, time is of the essence. For every minute of delay in treatment, people typically lose almost two million brain cells. Yet a new study presented at the Canadian Stroke Congress reveals that those delays - in getting the right tests and the right drugs - can be longer when people experience a stroke in a hospital.
A group of leading entrepreneurs and innovators will be gathering at the Royal Society of Medicine on Saturday 16 April to take part in the Society's 12th Medical Innovations Summit. Providing a twice-yearly platform for the presentation and discussion of inspirational ideas and developments in the field of medicine and healthcare, the Summits encourage innovators at the very beginning of their careers, as well as established clinicians and academics.
Takeda Pharmaceutical Company Limited today announced top-line results from the international, randomized, placebo-controlled, double-blind GEMINI II pivotal phase 3 trial. The trial evaluated vedolizumab in 1,115 patients with moderately to severely active Crohn's disease who have failed at least one conventional therapy, including TNFα antagonists.
› Verified 6 days ago
| Entity Name | Upmc Hillman Cancer Center-pinnacle |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275163362 PECOS PAC ID: 4284044934 Enrollment ID: O20201109000151 |
News Archive
Celgene International Sàrl announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality. REVLIMID was also approved in June 2010 in combination with dexamethasone, for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy.
Isis Pharmaceuticals, Inc. announced today that it has initiated a Phase 1 study for ISIS-GSK3Rx and earned a $3 million milestone payment from GlaxoSmithKline.
At the first sign of a stroke, time is of the essence. For every minute of delay in treatment, people typically lose almost two million brain cells. Yet a new study presented at the Canadian Stroke Congress reveals that those delays - in getting the right tests and the right drugs - can be longer when people experience a stroke in a hospital.
A group of leading entrepreneurs and innovators will be gathering at the Royal Society of Medicine on Saturday 16 April to take part in the Society's 12th Medical Innovations Summit. Providing a twice-yearly platform for the presentation and discussion of inspirational ideas and developments in the field of medicine and healthcare, the Summits encourage innovators at the very beginning of their careers, as well as established clinicians and academics.
Takeda Pharmaceutical Company Limited today announced top-line results from the international, randomized, placebo-controlled, double-blind GEMINI II pivotal phase 3 trial. The trial evaluated vedolizumab in 1,115 patients with moderately to severely active Crohn's disease who have failed at least one conventional therapy, including TNFα antagonists.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Scott C Felter I, DO 101 Erford Rd Ste 101, Camp Hill, PA 17011-1802 Ph: () - | Scott C Felter I, DO 101 Erford Rd, Suite 101, Camp Hill, PA 17011-1802 Ph: (717) 975-8900 |
News Archive
Celgene International Sàrl announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality. REVLIMID was also approved in June 2010 in combination with dexamethasone, for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy.
Isis Pharmaceuticals, Inc. announced today that it has initiated a Phase 1 study for ISIS-GSK3Rx and earned a $3 million milestone payment from GlaxoSmithKline.
At the first sign of a stroke, time is of the essence. For every minute of delay in treatment, people typically lose almost two million brain cells. Yet a new study presented at the Canadian Stroke Congress reveals that those delays - in getting the right tests and the right drugs - can be longer when people experience a stroke in a hospital.
A group of leading entrepreneurs and innovators will be gathering at the Royal Society of Medicine on Saturday 16 April to take part in the Society's 12th Medical Innovations Summit. Providing a twice-yearly platform for the presentation and discussion of inspirational ideas and developments in the field of medicine and healthcare, the Summits encourage innovators at the very beginning of their careers, as well as established clinicians and academics.
Takeda Pharmaceutical Company Limited today announced top-line results from the international, randomized, placebo-controlled, double-blind GEMINI II pivotal phase 3 trial. The trial evaluated vedolizumab in 1,115 patients with moderately to severely active Crohn's disease who have failed at least one conventional therapy, including TNFα antagonists.
› Verified 6 days ago
Dr. Krishna Reddy Dondeti, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 503 N 21st St, Camp Hill, PA 17011 Phone: 717-972-4448 Fax: 717-972-7366 | |
Mohammad Shahriar Hussain Rumi, MBBS Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 503 N 21st St, Camp Hill, PA 17011 Phone: 717-972-4448 Fax: 717-972-7366 | |
George Ezeji, M.D Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 205 Grandview Ave Ste 301, Camp Hill, PA 17011 Phone: 717-695-0394 Fax: 717-695-0398 | |
Dr. Amit Kumar Misra, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 503 N 21st St, Camp Hill, PA 17011 Phone: 717-972-4448 Fax: 717-972-7366 | |
Maurice J. Lewis, M.D. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 890 Poplar Church Rd, Suite 508, Camp Hill, PA 17011 Phone: 717-761-3875 Fax: 717-761-7893 | |
Dr. Robert Denes Kusztos, MD Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 4400 Carlisle Pike, Camp Hill, PA 17011 Phone: 717-975-9800 Fax: 717-975-5509 | |
Dr. Chandrasekhar Reddy Dinasarapu, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 503 N. 21st Street, Camp Hill, PA 17011 Phone: 717-972-4448 Fax: 717-972-7366 |